ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,048Medicare Part D Prescriptions Filled, Including Refills

Rank: 138 out of 670

$823K Total Retail Price of All Prescriptions

Rank: 65 out of 670

549 Patients Receiving at Least One Drug in Part D
80%Patients 65 Years and Older
18% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in West Virginia
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 549 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

18% of this provider’s 549 patients filled at least one prescription for a schedule three drug, compared to an average of 16%.

Risky Drugs to Seniors

3% of this provider’s 8,246 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

26% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$82 was the average price of a prescription from this provider, compared to $58 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in West Virginia
HYDROCODONE-ACETAMINOPHEN 417 276 S3 1 1
LISINOPRIL 366 285 2 3
OMEPRAZOLE 306 256 3 5
AMLODIPINE BESYLATE 288 248 4 7
LEVOTHYROXINE SODIUM 213 185 5 2
METFORMIN HCL 203 127 6 8
SIMVASTATIN 192 163 7 4
WARFARIN SODIUM 186 179 8 13
ZOLPIDEM TARTRATE 182 123 9 23
FUROSEMIDE 163 156 10 6
HYDROCHLOROTHIAZIDE 161 133 11 10
METOPROLOL TARTRATE 160 129 12 9
GLYBURIDE-METFORMIN HCL 114 107 R 13 157
GABAPENTIN 110 76 14 11
PANTOPRAZOLE SODIUM 106 87 15 41
ATENOLOL 106 98 15 17
SYNTHROID 103 93 17 47
ALPRAZOLAM 102 91 18 138
AMLODIPINE BESYLATE-BENAZEPRIL 101 94 19 74
NEXIUM 98 84 20 14
DIOVAN 98 68 20 48
CITALOPRAM HBR 97 65 22 20
ATORVASTATIN CALCIUM 94 78 23 15
DICLOFENAC SODIUM 92 52 24 110
LISINOPRIL-HYDROCHLOROTHIAZIDE 91 72 25 27
TERAZOSIN HCL 90 84 26 137
TRAMADOL HCL 89 57 27 21
CLOPIDOGREL 87 81 28 24
PROAIR HFA 80 72 29 28
CRESTOR 79 73 30 18
DONEPEZIL HCL 78 78 31 31
AZITHROMYCIN 77 67 32 35
ALLOPURINOL 75 57 33 38
GLYBURIDE 74 63 R 34 85
METOPROLOL SUCCINATE 73 62 35 12
METFORMIN HCL ER 70 55 36 63
ALENDRONATE SODIUM 70 70 36 43
PLAVIX 66 64 38 34
CLONIDINE HCL 66 57 38 62
SERTRALINE HCL 65 62 40 22
PAROXETINE HCL 65 59 40 52
OXAPROZIN 61 51 42 311
LOVASTATIN 59 51 43 44
VERAPAMIL ER 59 43 43 94
ONGLYZA 58 58 45 186
PROPRANOLOL HCL 57 48 46 130
NAPROXEN 56 34 47 81
DILTIAZEM 24HR ER 56 38 47 122
PRAVASTATIN SODIUM 56 49 47 19
POTASSIUM CHLORIDE 54 49 50 16
GLIMEPIRIDE 53 41 51 32
SULFAMETHOXAZOLE-TRIMETHOPRIM 52 35 52 93
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on March 31, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.